Skip to main content

Table 2 Univariate analysis of the effects of clinicopathological characteristics on survival in 7103 GCA patients treated with different surgical approaches

From: Transthoracic, thoracoabdominal, and transabdominal surgical approaches for gastric cardia adenocarcinomas: a survival evaluation based on a cohort of 7103 patients

Characteristics Median survival (95% CI) Pa Pb
Transthoracic Thoracoabdominal Transabdominal
Sex
 Male 5.66 (5.37–5.94) 4.66 (4.27–5.05) 3.84 (3.15–4.53)  < 0.001*  < 0.001
 Female 5.69 (5.08–6.29) 5.73 (3.53–7.94) 4.79 (3.60–5.98) 0.32
Age (years)
  < 40 5.02 (1.93–8.12) 3.29 (0.34–6.24) Not reached 0.34  < 0.001
 40–49 7.27 (5.23–9.31) 7.27 (5.33–9.22) 3.55 (1.98–5.12) 0.10
 50–59 7.04 (6.34–7.74) 4.95 (4.19–5.71) 6.268 (4.22–8.32) 0.02
 60–69 5.68 (5.31–6.04) 4.73 (4.05–5.40) 4.088 (3.33–4.84) 0.002†
 70–79 4.00 (3.65–4.36) 3.50 (2.19–4.82) 2.70 (1.72–3.68) 0.005‡
  ≥ 80 3.51 (2.84–4.18) 3.55 (1.49–5.61) 1.22 (0.56–1.88) 0.16
Tumor stage
 0/I 13.09 (8.90–17.27) 9.39 (4.49–14.29) Not reached 0.60  < 0.001
 II 7.70 (7.08–8.33) 7.02 (5.26–8.78) 6.95 (2.61–11.28) 0.41
 III 4.23 (4.02–4.45) 3.79 (3.31–4.27) 3.16 (2.58–3.73)  < 0.001
 IV 4.99 (3.60–6.38) 3.09 (1.51–4.68) 3.01 (1.53–4.50) 0.03
N stage
 N0 8.99 (8.23–9.75) 8.51 (6.38–10.64) 6.95 (2.67–11.22) 0.31  < 0.001
 N1 4.46 (4.26–4.67) 3.93 (3.55–4.31) 3.16 (2.66–3.67)  < 0.001
  1. *Transthoracic vs. thoracoabdominal, P < 0.001; transthoracic vs. transabdominal, P < 0.001; thoracoabdominal vs. transabdominal, P = 0.08
  2. †Transthoracic vs. thoracoabdominal, P = 0.12; transthoracic vs. transabdominal, P = 0.001; thoracoabdominal vs. transabdominal, P = 0.08
  3. ‡Transthoracic vs. thoracoabdominal, P = 0.20; transthoracic vs. transabdominal, P = 0.001; thoracoabdominal vs. transabdominal, P = 0.14